Discovery of novel SOS1 inhibitors using machine learning

Lihui Duo1, Yi Chen2,3, Qiupei Liu1,2

  • 1Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute, Key Laboratory for Carbonaceous Waste Processing and Process Intensification Research of Zhejiang Province, Department of Chemical and Environmental Engineering, The University of Nottingham Ningbo China 199 Taikang East Road Ningbo 315100 P. R. China Jianfeng.Ren@nottingham.edu.cn Bencan.Tang@nottingham.edu.cn.

PubMed

Insights

Machine learning identified novel SOS1 inhibitors for RAS-driven cancers. Nine compounds with unique structures show potent inhibition, with CL01545365 demonstrating promising drug-like properties for therapeutic development.

Area of Science:

  • Oncology
  • Pharmacology
  • Computational Chemistry

Background:

  • RAS signaling pathway overactivation drives 30% of human cancers.
  • Son of sevenless 1 (SOS1) is a key regulator of RAS activation, making it a therapeutic target for RAS-driven malignancies.

Purpose of the Study:

  • To identify novel small-molecule inhibitors of SOS1 using machine learning-based virtual screening.
  • To explore new chemical scaffolds for SOS1 inhibition in cancer therapy.

Main Methods:

  • Utilized a random forest regressor for virtual screening of large compound libraries (L-series, EGFR-related, and CNCL).
  • Evaluated inhibitory activity using KRAS G12C/SOS1 protein-protein interaction (PPI) assays.
  • Performed molecular docking and in silico drug-likeness assessments.

Main Results:

  • Discovered nine novel compounds with unexplored chemical frameworks exhibiting SOS1 inhibitory activity.
  • The most potent compound achieved >50% inhibition and an IC50 near 20 μg mL−1.
  • Hit compounds, like CL01545365, bind to a unique pocket within the target, distinct from known inhibitors.

Conclusions:

  • Novel SOS1 inhibitors with unique binding modes were identified from the carboxylic acid series.
  • These compounds represent promising candidates for developing new therapeutics against RAS-driven cancers.
  • The findings highlight the potential of ML-driven VS in discovering novel drug scaffolds.

Related Concept Videos

Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
4.6K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129